In recent studies with TRAIL-resistant cancer cells, we have observed that treatment with a combination of TRAIL and PPARγ ligand Troglitazone (TZD) induces profound apoptosis compared to either agent alone [33]. This evidence concerns the gene TNFSF10 and cancer.